INS and hyperlipidemia: Yet, a β-cell specific THR agonist, similar to the one designed for liver to treat hyperlipidemia [[100], [101], [102]] could be developed to induce proliferation of β-cells as a potential therapeutic for both type 1 and type 2 diabetes where there is a deficiency in functional insulin producing cells.